瑞典以价值为基础的医疗保健:达到新的水平(英文)

VALUE-BASED HEALTHCARE IN SWEDENReaching the next levelCommissioned by© The Economist Intelligence Unit Limited 20191Value-based healthcare in SwedenReaching the next levelContents2 List of abbreviations3 About this report4 Executive summary and key findings6 Introduction7 Chapter 1: The Swedish model and lessons for others14 Chapter 2: The backlash and obstacles to further progress21 Chapter 3: Overcoming limitations and potential steps forward29 Conclusion© The Economist Intelligence Unit Limited 20192Value-based healthcare in SwedenReaching the next levelList of abbreviationsAI: artificial intelligenceEHR: electronic health recordEUnetHTA: European Network for Health Technology AssessmentNQR: Swedish national healthcare quality registryRWD: real-world dataRWE: real-world evidenceSALAR: Swedish Association of Local Authorities and RegionsTLV: Tandvårds-Och Läkemedelsförmånsverket (Dental and Pharmaceutical Benefits Agency)VBHC: value-based healthcareVBP: value-based payment© The Economist Intelligence Unit Limited 20193Value-based healthcare in SwedenReaching the next levelAbout this reportValue-based healthcare in Sweden: Reaching the next level is an Economist Intelligence Unit report, commissioned by Takeda. It looks at Sweden’s progress on implementing the principles of value-based healthcare (VBHC) throughout the country and care pathways.The findings of the report are based on desk research and ten in-depth interviews with experts on VBHC in Sweden, including health economists, healthcare providers and policymakers. Our thanks are due to the following for their time and insights (listed alphabetically):• Karin Göransson, policy analyst, Swedish Association of Local Authorities and Regions (SALAR)• Peter Graf, CEO, Tiohundra• Niklas Hedberg, chief pharmacist, Dental and Pharmaceutical Benefits Agency/Tandvårds-Och Läkemedelsförmånsverket (TLV); and chair of the executive board, European HTA Network (EUnetHTA)• Morten Kildal, consultant plastic surgeon, head of value-based healthcare and associate professor, Uppsala University Hospital• Peter Lindgren, managing director, Swedish Institute for Health Economics• Tobias Nilsson, chief of strategy, Västra Götaland healthcare region• Jörgen Nordenström, emeritus professor of surgery, and freelance consultant in healthcare quality improvement projects, VBMCare.com• Fredrik Öhrn, senior innovation manager, Karolinska University Hospital• Johan Thor, associate professor, Jönkoping Academy for Improvement of Health and Welfare• Fredrik Westander, senior policy analyst, SALAR• Jonas Wohlin, founder, IvbarThe report was written by Andrea Chipman and edited by Martin Koehring of The Economist Intelligence Unit.January 2019© The Economist Intelligence Unit Limited 20194Value-based healthcare in SwedenReaching the next levelExecutive summaryThe need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people wit

立即下载
医药生物
2019-06-29
经济学人智库
32页
0.48M
收藏
分享

[经济学人智库]:瑞典以价值为基础的医疗保健:达到新的水平(英文),点击即可下载。报告格式为PDF,大小0.48M,页数32页,欢迎下载。

本报告共32页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共32页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
康龙化成业绩预测和估值指标
医药生物
2019-06-19
来源:医药外包行业系列深度报告之二:内资药企需求高增长,助力医药研发合同外包服务产业第三波浪潮
查看原文
康龙化成可比公司估值(收盘价截至 2019 年 5 月 31 日)
医药生物
2019-06-19
来源:医药外包行业系列深度报告之二:内资药企需求高增长,助力医药研发合同外包服务产业第三波浪潮
查看原文
康龙化成和药明康德对比
医药生物
2019-06-19
来源:医药外包行业系列深度报告之二:内资药企需求高增长,助力医药研发合同外包服务产业第三波浪潮
查看原文
康龙化成研发后端业务占比提升 图 24:康龙化成近年毛利率、净利率均呈提升趋势
医药生物
2019-06-19
来源:医药外包行业系列深度报告之二:内资药企需求高增长,助力医药研发合同外包服务产业第三波浪潮
查看原文
康龙化成 18 年收入 29 亿,增长 27% 图 22:康龙化成 18 年国内客户收入贡献 10%
医药生物
2019-06-19
来源:医药外包行业系列深度报告之二:内资药企需求高增长,助力医药研发合同外包服务产业第三波浪潮
查看原文
昭衍新药业绩预测和估值指标
医药生物
2019-06-19
来源:医药外包行业系列深度报告之二:内资药企需求高增长,助力医药研发合同外包服务产业第三波浪潮
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起